Related Experiment Video
Updated: Feb 27, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
The Impact of Cardio-Renal-Metabolic Profile in Dilated Cardiomyopathy
Tamim Akbari1,2, Daniel J Hammersley1,2,3, Clarice Yau-Yee May2
1Royal Brompton and Harefield Hospitals, Part of Guy's and St Thomas' NHS Foundation Trust, London, UK.
Insights
Dilated cardiomyopathy patients often have metabolic syndrome and renal disease, worsening prognosis. Optimizing cardio-renal-metabolic health is crucial for better outcomes in these complex cases.
Area of Science:
- Cardiology
- Nephrology
- Metabolic Diseases
Background:
- Dilated cardiomyopathy is a major cause of heart failure globally.
- Aging populations and increasing multimorbidity exacerbate heart failure challenges.
Purpose of the Study:
- To describe the prevalence of metabolic syndrome and renal failure in dilated cardiomyopathy patients.
- To explore common underlying mechanisms and evaluate outcomes.
- To highlight novel therapeutic strategies for this patient group.
Main Methods:
- This is a review article.
- It synthesizes current literature on dilated cardiomyopathy, metabolic syndrome, and renal disease.
- Focuses on pathophysiological pathways and treatment strategies.
Main Results:
- A significant number of dilated cardiomyopathy patients present with concurrent metabolic syndrome and renal disease.
- This multimorbidity is associated with a worse prognosis and complex treatment challenges.
- Shared pathophysiological pathways complicate management.
Conclusions:
- Optimizing the cardio-renal-metabolic profile is essential for managing dilated cardiomyopathy.
- New therapeutic strategies targeting shared pathways are needed to improve patient outcomes.
Purpose Of Review:
Dilated cardiomyopathy is an important contributor to heart failure burden worldwide. With an aging population and rising multimorbidity, in this review, we describe the prevalence of metabolic syndrome and renal failure in patients with dilated cardiomyopathy and focus on common underlying mechanisms, evaluate outcomes in these patients and highlight newer therapeutic strategies.
Recent Findings:
A significant proportion of patients with dilated cardiomyopathy has concomitant metabolic syndrome and renal disease. This combination of multimorbidity portends worse prognosis and often presents unique challenges in treatment given the complex interplay and shared pathophysiological pathways. Optimization of the cardio-renal-metabolic profile should be a key consideration in the management of patients with dilated cardiomyopathy. Therapeutic strategies targeting common pathophysiological pathways are needed in order to improve overall outcomes.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Heart Failure Drugs: Diuretics

